In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages

  Alou, Luis ^a   Giménez, María José ^a   Cafini, Fabio ^a   Aguilar, Lorenzo ^a   Sevillano, David ^a   González, Natalia ^a   Torrico, Martha ^a   Prieto, José ^a   García Rey, César ^b   García Escribano, Nuria ^b  

^a SCHOOL OF MEDICINE   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Acinetobacter; E. coli; Enterococci; Killing curves; MRSA; Protein binding

Indexed keywords

HUMAN ALBUMIN; TIGECYCLINE; VANCOMYCIN; ALB PROTEIN, HUMAN; ALBUMINOID; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; GLYCOPROTEIN; MINOCYCLINE; SERUM ALBUMIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; BACTERIAL COUNT; CHEMISTRY; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; PROTEIN BINDING;

ACINETOBACTER BAUMANNII; ALBUMINS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; CULTURE MEDIA; ENTEROCOCCUS FAECIUM; GLYCOPROTEINS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MINOCYCLINE; PROTEIN BINDING; SERUM ALBUMIN;

EID: 76249093977     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp371     Document Type: Article

References (10)

1. Cafini F, Aguilar L, González N et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007; 59: 1185-9.
2. Sevillano D, Giménez MJ, Alou L et al. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2007; 60: 156-8.
3. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Growth Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
5. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, PA, USA, 1999.
6. Van Wart SA, Cirincione BB, Ludwig EA et al. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007; 47: 727-37.
7. Tsuji BT, Leonard SN, Rhomberg PR et al. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis 2008; 60: 441-4.
8. British Society for Antimicrobial Chemotherapy. http://www.bsac.org.uk/susceptibility_testing/breakpoints.cfm (7 May 2009, date last accessed).
9. Food and Drug Administration. Tygacil Label Information. http://www.fda.gov/cder/foi/label/2007/021821s010lbl.pdf (7 May 2009, date last accessed).
10. European Society of Clinical Microbiology and Infectious Diseases. http://www.srga.org/eucastwt/MICTAB/MICtetracyclines.htm (7 May 2009, date last accessed).